Unknown

Dataset Information

0

Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study.


ABSTRACT:

Background

Cancer-related microangiopathic haemolytic anaemia (MAHA) is a rare but life-threatening paraneoplastic syndrome. Only single cases or small series have been reported to date. We set up a retrospective multicentre study focusing on breast cancer-related MAHA.

Methods

Main inclusion criteria were known diagnosis of breast cancer, presence of schistocytes and either low haptoglobin or cytopenia and absence of any causes of MAHA other than breast cancer, including gemcitabine- or bevacizumab-based treatment. Patient characteristics, treatments and outcome were retrieved from digital medical records.

Results

Individual data from 54 patients with breast cancer-related MAHA were obtained from 7 centres. Twenty-three (44%) patients had a breast tumour with lobular features, and most primary tumours were low grade (grade I/II, N =?39, 75%). ER+/HER2-, HER2+ and triple-negative phenotypes accounted for N =?33 (69%), N =?7 (15%) and N =?8 (17%) cases, respectively. All patients had stage IV cancer at the time of MAHA diagnosis. Median overall survival (OS) was 28?days (range 0-1035; Q1:10, Q3:186). Independent prognostic factors for early death (??28?days) were PS?>?2 (OR?=?7.0 [1.6; 31.8]), elevated bilirubin (OR?=?6.9 [1.1; 42.6]), haemoglobin ConclusionsBreast cancer-related MAHA appears to be a new feature of invasive lobular breast carcinoma. Prognostic factors and scores may guide clinical decision-making in this serious but not always fatal condition.

SUBMITTER: Alhenc-Gelas M 

PROVIDER: S-EPMC7814553 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Cancer-related microangiopathic haemolytic anaemia (MAHA) is a rare but life-threatening paraneoplastic syndrome. Only single cases or small series have been reported to date. We set up a retrospective multicentre study focusing on breast cancer-related MAHA.<h4>Methods</h4>Main inclusion criteria were known diagnosis of breast cancer, presence of schistocytes and either low haptoglobin or cytopenia and absence of any causes of MAHA other than breast cancer, including gemcitab  ...[more]

Similar Datasets

| S-EPMC1755024 | biostudies-literature
| S-EPMC3003239 | biostudies-literature
| S-EPMC10617271 | biostudies-literature
| S-EPMC4433506 | biostudies-literature
| S-EPMC5546083 | biostudies-other
| S-EPMC7055020 | biostudies-literature
| S-EPMC5152924 | biostudies-literature
| S-EPMC8002719 | biostudies-literature
| S-EPMC9026206 | biostudies-literature
| S-EPMC4246399 | biostudies-literature